ViewPoint Therapeutics is a biotechnology company which develops treatments for diseases of protein misfolding, including cataracts. To address the need for new methods to treat cataracts and presbyopia, the Company is developing crystallin stabilizers, such as VP1-001, a molecule designed to stabilize the functional form of the crucial human lens protein alpha-crystallin against accumulated damage.
|Employees (est.) (Jan 2020)||15||(-6%)|
ViewPoint Therapeutics total Funding
ViewPoint Therapeutics latest funding size
Time since last funding
|2 years ago|
ViewPoint Therapeutics investors
|Novo Ventures, Mission Bay Capital, Biotechnology Value Fund, Lagunita BioSciences LLC, The Rise Fund|
When was ViewPoint Therapeutics founded?
ViewPoint Therapeutics was founded in 2014.
Who are ViewPoint Therapeutics key executives?
ViewPoint Therapeutics's key executives are Leah Makley and Brian Connolly.
How many employees does ViewPoint Therapeutics have?
ViewPoint Therapeutics has 15 employees.
Who are ViewPoint Therapeutics competitors?
Competitors of ViewPoint Therapeutics include Nordic Nanovector, NeuroVive Pharmaceutical and Y-mAbs Therapeutics.
Receive alerts for 300+ data fields across thousands of companies